Noven Announces New Finance Appointments

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN), today announced new finance and accounting appointments at Noven and Novogyne Pharmaceuticals.

Diane M. Barrett, age 39, has joined Noven as Treasurer and Executive Director of Finance, reporting to James B. Messiry, Noven's Chief Financial Officer. From 1997 though June 2000, Ms. Barrett served as Vice President and Chief Financial Officer of Bionumerik Pharmaceuticals, Inc., a pharmaceutical company specializing in mechanism-based drug discovery. From 1990 to 1997, she served in various senior finance roles, including as Treasurer and Director of Finance, with Cordis Corporation, a publicly-traded medical device company acquired by Johnson & Johnson in 1996. She was a Manager with Arthur Andersen prior to joining Cordis.

Leonard Maniscalco, age 45, will work primarily on Novogyne Pharmaceuticals' financial and accounting issues, reporting to Ms. Barrett. Novogyne is a rapidly-growing women's health company owned jointly by Noven and Novartis Pharmaceuticals. Mr. Maniscalco has served Noven since 1997 in various senior finance capacities, and has played an instrumental role in the establishment and growth of Novogyne.

"Both Noven and Novogyne are experiencing robust growth," said Robert Strauss, Noven's President & Chief Executive Officer. "As a result, we are strengthening both organizations with seasoned, dedicated finance and accounting executives. Diane and Len are proven performers whom I've known for years, and I'm confident that they'll help maximize the operations and prospects of both companies going forward."

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of transdermal and transmucosal drug delivery systems and technologies. Noven has developed and presently manufactures a series of leading-edge products, including the world's smallest estrogen transdermal delivery system, the United States' only combination estrogen/progestin transdermal delivery system, and the first transmucosal patch approved for marketing by the U.S. Food and Drug Administration. With a wide range of additional products in development, Noven is committed to becoming the world's premier developer, manufacturer, and marketer of transdermal and transmucosal drug delivery systems. For additional information on Noven, visit

Forward looking statements contained in this release are qualified by and subject to the risks and uncertainties specified by Noven in its most recent filings with the Securities and Exchange Commission.